Literature DB >> 22968365

[Treatment of nausea and vomiting with prokinetics and neuroleptics in palliative care patients : a review].

G Benze1, B Alt-Epping, A Geyer, F Nauck.   

Abstract

BACKGROUND: Many recommendations concerning the treatment of nausea and vomiting in palliative care patients exist but what is the evidence for this? Most studies dealing with this topic have focused on cancer patients under chemotherapy and/or radiation therapy or on patients with postoperative nausea. Cancer patients without chemotherapy or radiation therapy, patients without postoperative nausea, and patients having other diseases with palliative care aspects, such as acquired immunodeficiency syndrome (AIDS), chronic obstructive pulmonary disease (COPD), progressive heart failure, amyotrophic lateral sclerosis (ALS) and multiple sclerosis (MS) have been underrepresented in studies on nausea and vomiting so far.
OBJECTIVES: The aim of this review was to determine the level of evidence for the treatment of nausea and vomiting with prokinetics and neuroleptics in palliative care patients suffering from far advanced cancer and no longer being treated with chemotherapy or radiation therapy, AIDS, COPD, progressive heart failure, ALS or MS.
METHODS: Two different electronic databases (PubMed und Embase) were used to identify studies. Furthermore, a hand search for related articles was performed. No restriction was made concerning study types. Studies with patients undergoing chemotherapy radiation therapy or suffering from postoperative nausea, pediatric studies and studies published neither in English nor in German were excluded.
RESULTS: A total of 30 studies fulfilling the inclusion criteria were found. All studies focused on cancer patients. Despite intensive research studies in patients with AIDS, COPD, heart failure, ALS or MS were not detected. Metoclopramide is seen as an effective drug in many studies whereas the evidence for it is moderate at best. Within the group of neuroleptics, levosupiride and levomepromazine seem to have good antiemetic potential but the evidence level is low.
CONCLUSION: In patients with advanced cancer not being treated with chemotherapy or radiation therapy, metoclopramide can be used to reduce nausea and vomiting. Neuroleptics, such as levosulpiride or levomepromazine are alternatives but their adverse effects have to be considered carefully. The evidence level for prokinetics and neuroleptics is moderate to low. Concerning palliative care of patients with diseases other than cancer no studies exist. More well designed studies in palliative care patients are needed in order to facilitate evidence based antiemetic therapy. The English full text version of this article will be available in SpringerLink as of November 2012 (under "Supplemental").

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22968365     DOI: 10.1007/s00482-012-1216-7

Source DB:  PubMed          Journal:  Schmerz        ISSN: 0932-433X            Impact factor:   1.107


  82 in total

Review 1.  Treatment of nausea and vomiting in advanced cancer.

Authors:  M P Davis; D Walsh
Journal:  Support Care Cancer       Date:  2000-11       Impact factor: 3.603

Review 2.  Daily symptom burden in end-stage chronic organ failure: a systematic review.

Authors:  D J A Janssen; M A Spruit; E F M Wouters; J M G A Schols
Journal:  Palliat Med       Date:  2008-09-18       Impact factor: 4.762

Review 3.  Which antiemetic?

Authors:  I Lichter
Journal:  J Palliat Care       Date:  1993       Impact factor: 2.250

4.  Patient reports of symptoms and their treatment at three palliative care projects servicing individuals with HIV/AIDS.

Authors:  Daniel Karus; Victoria H Raveis; Carla Alexander; Barbara Hanna; Peter Selwyn; Katherine Marconi; Irene Higginson
Journal:  J Pain Symptom Manage       Date:  2005-11       Impact factor: 3.612

5.  An assessment of aetiology-based guidelines for the management of nausea and vomiting in patients with advanced cancer.

Authors:  Jeffrey Stephenson; Andrew Davies
Journal:  Support Care Cancer       Date:  2005-10-15       Impact factor: 3.603

Review 6.  A systematic review of the treatment of nausea and/or vomiting in cancer unrelated to chemotherapy or radiation.

Authors:  Mellar P Davis; Gretchen Hallerberg
Journal:  J Pain Symptom Manage       Date:  2010-04       Impact factor: 3.612

7.  Comparison of the efficacy, safety, and pharmacokinetics of controlled release and immediate release metoclopramide for the management of chronic nausea in patients with advanced cancer.

Authors:  E D Bruera; T J MacEachern; K A Spachynski; D F LeGatt; R N MacDonald; N Babul; Z Harsanyi; A C Darke
Journal:  Cancer       Date:  1994-12-15       Impact factor: 6.860

Review 8.  Metoclopramide-induced movement disorders. Clinical findings with a review of the literature.

Authors:  L G Miller; J Jankovic
Journal:  Arch Intern Med       Date:  1989-11

9.  The prevalence of metoclopramide-induced tardive dyskinesia and acute extrapyramidal movement disorders.

Authors:  L Ganzini; D E Casey; W F Hoffman; A L McCall
Journal:  Arch Intern Med       Date:  1993-06-28

10.  Impact of symptom prevalence and symptom burden on quality of life in patients with heart failure.

Authors:  Cheryl Hoyt Zambroski; Debra K Moser; Geetha Bhat; Craig Ziegler
Journal:  Eur J Cardiovasc Nurs       Date:  2005-09       Impact factor: 3.908

View more
  1 in total

1.  [Treatment of nausea and vomiting with 5HT3 receptor antagonists, steroids, antihistamines, anticholinergics, somatostatinantagonists, benzodiazepines and cannabinoids in palliative care patients : a systematic review].

Authors:  G Benze; A Geyer; B Alt-Epping; F Nauck
Journal:  Schmerz       Date:  2012-09       Impact factor: 1.107

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.